Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 3/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973338 | 0.90 | BRD4 (0.44) | EHMT2BRD4RAPGEF4 | |
| SCHEMBL1842397 | 0.79 | RAPGEF4 (0.46) | EHMT2BRD4CHEK1RAPGEF4MAPK1 | |
| SCHEMBL20353196 | 0.78 | TAS1R3 (0.51) | RAPGEF4 | |
| SCHEMBL14577966 | 0.77 | BRD4 (0.42) | EHMT2BRD4 | |
| SCHEMBL24171954 | 0.75 | ITK (0.52) | BRD4CHEK1PRKCZ | |
| SCHEMBL4166429 | 0.74 | BRD4 (0.51) | BRD4 | |
| SCHEMBL9312434 | 0.73 | SYK (0.54) | BRD4PRKCZMAPK1 | |
| SCHEMBL27583230 | 0.72 | PRKCZ (0.52) | BRD4CHEK1PRKCZPRKD2 | |
| SCHEMBL20281444 | 0.72 | BRD4 (0.47) | EHMT2BRD4IL1BCHEK1PRKCZ | |
| SCHEMBL10192577 | 0.71 | PRKCZ (0.49) | BRD4CHEK1PRKCZPRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579340-B2 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | PFIZER INC (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | EHMT2 2190/4885BRD4 1957/4885IL1B 1562/4885 |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | EHMT2 2190/4885BRD4 1957/4885IL1B 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.